Trial Profile

A head-to-head clinical phase 1b trial of the APG777 in combination with APG990 (APG279 program) against Dupixent in moderate-to-severe AD of APG279

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 05 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

28 Feb 2025 trial event According to an Apogee Therapeutics media release, the Company will host a conference call and webcast at 8:30am ET to discuss the results and plans for its combination approach for APG777 + APG990.
19 Aug 2024 According to an Apogee Therapeutics media release, pending positive results from the Phase 1 clinical trial and following submission of an Investigational New Drug application or foreign equivalent, company plans to initiate the first clinical trial of the APG777 and APG990 combination in 2025.
16 Aug 2024 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com